Loading people...
Jason Camm is the Los Angeles, California-based Managing Director and Chief Medical Officer at Thiel Capital, a venture capital investment firm founded by Peter Thiel. In this executive role, he oversees the firm's global health, biotechnology, and life sciences portfolio, targeting Seed to Series B investments ranging from $100,000 to $1,500,000. Camm serves on the board of directors for multiple publicly traded biotechnology companies, including Chemomab Therapeutics and ATAI Life Sciences, where he guided the latter through its $225 million initial public offering in June 2021. Recognized as a Young Global Leader by the World Economic Forum in 2021, he previously earned a Master of Osteopathy degree from the British School of Osteopathy. His background combines clinical performance medicine with corporate governance to drive venture capital investments across emerging healthcare technologies, medical devices, and longevity therapeutics.
Jason Camm is a distinguished Managing Director at Thiel Capital, a leading investment firm renowned for its strategic and often contrarian approach to venture capital. In his pivotal role, Mr. Camm is instrumental in identifying and nurturing companies poised for significant disruption and long-term growth. His expertise spans a diverse range of high-impact sectors, primarily focusing on cutting-edge advancements in biotech, longevity, deep technology, and artificial intelligence.
At Thiel Capital, Jason Camm contributes to the firm's mission of investing in foundational technologies and businesses that redefine industries. He is deeply involved in evaluating opportunities within life sciences, health technology, and other frontier areas where scientific breakthroughs meet market potential. His investment philosophy aligns with Thiel Capital's commitment to backing visionary founders and innovative solutions that address complex global challenges, from extending healthy human lifespans to developing transformative AI applications.
Before his tenure as Managing Director at Thiel Capital, Jason Camm built a robust career marked by entrepreneurial ventures and strategic advisory roles. His background provided him with a unique perspective on technology and healthcare landscapes, equipping him with the foresight to spot emerging trends and disruptive business models. This extensive experience underpins his ability to guide portfolio companies through critical growth phases, offering strategic insights that extend beyond mere capital injection.
While specific individual investments by Jason Camm are often part of Thiel Capital's broader portfolio strategy, his work contributes to the firm's track record of backing influential companies. Thiel Capital is known for its early support of transformative enterprises, and Mr. Camm's focus areas reflect this legacy, targeting ventures that promise to reshape the future. His strategic vision and deep industry knowledge make him a key figure in the venture capital ecosystem, driving innovation in some of the most critical and rapidly evolving sectors.
Jason Camm is a Managing Director at Thiel Capital, an investment firm known for its focus on disruptive technologies and long-term growth. He plays a key role in identifying and supporting innovative companies.
Jason Camm primarily invests in companies within the biotech, longevity, deep technology, and artificial intelligence sectors. His focus is on groundbreaking advancements that have the potential to redefine industries.
Jason Camm works as a Managing Director at Thiel Capital, a prominent investment firm founded by Peter Thiel. The firm is headquartered in Los Angeles, California.
